| Literature DB >> 35888997 |
Oana Lelia Pop1,2, Ramona Suharoschi1,2, Rosita Gabbianelli3.
Abstract
Probiotic consumption is recognized as being generally safe and correlates with multiple and valuable health benefits. However, the mechanism by which it helps detoxify the body and its anti-carcinogenic and antimutagenic potential is less discussed. A widely known fact is that globalization and mass food production/cultivation make it impossible to keep all possible risks under control. Scientists associate the multitude of diseases in the days when we live with these risks that threaten the population's safety in terms of food. This review aims to explore whether the use of probiotics may be a safe, economically viable, and versatile tool in biodetoxification despite the numerous risks associated with food and the limited possibility to evaluate the contaminants. Based on scientific data, this paper focuses on the aspects mentioned above and demonstrates the probiotics' possible risks, as well as their anti-carcinogenic and antimutagenic potential. After reviewing the probiotic capacity to react with pathogens, fungi infection, mycotoxins, acrylamide toxicity, benzopyrene, and heavy metals, we can conclude that the specific probiotic strain and probiotic combinations bring significant health outcomes. Furthermore, the biodetoxification maximization process can be performed using probiotic-bioactive compound association.Entities:
Keywords: anticarcinogen; antimutagen; detoxification; food contaminants; probiotics
Year: 2022 PMID: 35888997 PMCID: PMC9319832 DOI: 10.3390/microorganisms10071278
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Figure 1Possible risks caused by probiotics.
Figure 2Contaminations in the food.
Lactobacillus strains, their biodetoxification mechanisms, and rates for different food contaminants.
| Cell Count CFU/mL | Contaminant | Food/Environment | Contaminant Level | Biodetox. Mechanism | Detox. Rate | Ref. | |
|---|---|---|---|---|---|---|---|
| 109 | AFB1 |
milk in vitro digestion | 5 µg /mL |
absorption enzymatic degradation | 14–70% | [ | |
| OD10 | As |
in vivo—NCM460 colon epithelium cell HT29-MTX mucosecretory adenocarcinoma cells cooked white rice | 30 mg/kg |
binding | 1–6% | [ | |
| 108 | AFB1 |
cow milk | 1 µg /mL |
↓ bioaccessibility | 13.53–35.53% | [ | |
| 1, 5, 7 × 109 | AFB1, AFB2, AFG1, AFG2 |
in vitro in vivo (rats) | 50 µg /mL |
binding absorption | 95.59% | [ | |
| 106 |
Mueller–Hinton agar | 106 CFU/mL |
growth inhibition | 12.1 mm | [ | ||
| 108 9 10 | B[a]P |
in vitro | 1.0 μg/mL |
absorption | 45–60% | [ | |
| 108 |
|
in vitro (agar) | 106 spores/mL |
growth inhibition—antifungal activity | 20–50% | [ | |
| 1010 | Pb |
in vivo (BALB/c mice) | 50 mg/kg/day |
binding excretion | ↑ Pb excretion | [ | |
| 108 | ZEN |
maize kernels | 5 mg/L |
hydrolysis | 100% | [ | |
| 109 | Heavy metals |
living fish (rainbow trout) | - |
stop accumulation (vs. control) | na | [ | |
| 107 | Acrylamide |
whole-wheat bread | 47.6 µg /kg |
↓ Maillard reaction and acrylamide formation due to fermentation | 85.5% | [ | |
| 4.5 × 1010 | AFB1 |
in vivo—broiler chickens | 1 mg/kg |
↑ excretion | 41–68% | [ | |
| 109 | Hg |
in vivo—Wistar rats | 20 μg/mL of mercuric chloride |
↑ elimination | >50% | [ | |
| 1.6 × 105 |
ice cream |
growth inhibition | 27.6 ± 0.9 mm | [ | |||
| 1.6 × 105 | AFM1 |
ice cream | 0.5 µg /kg |
degradation | 26–52% | [ |
↓—decrease, ↑—increase, ZEN—zearolenone mycotoxin; AFB, AFM1—aflatoxin B1, M1; OTA—ochratoxin A; Pb—lead; Zn—zinc; Ni—nickel; Cd—cadmium; Hg—mercury, As—arsenic; B[a]P—benzo[a]pyrene, A—Aspergillus, L—Lactobacillus, S—Staphylococcus, Si—Shigella.
Bifidobacteria strains, their biodetoxification mechanisms, and rates for different food contaminates.
| Cell Count CFU/mL | Contaminant | Food/Environment | Contaminant Level | Biodetox. Mechanism | Detox. Rate | Ref. | |
|---|---|---|---|---|---|---|---|
|
| 5 × 108 | B[a]P |
in vitro—colon epithelial cells in vitro digestion | 0.5 µg /mL |
markedly relieved cell damage | 95% | [ |
| 108 |
in vitro | 106 CFU/mL |
DNA-DNA hybridization | 64.9%; 54% | [ | ||
| 5 × 108 | B[a]P |
in vitro | 100 μg/mL |
physical absorption xenobiotics biotransformation | 78% | [ | |
|
| 1; 5; 7 × 109 | AFB1, AFB2, AFG1, AFG2 |
in vitro in vivo (rats) | 50 µg /mL |
binding absorption | 95.59% | [ |
|
| 1 × 1011 | ZEN |
in vitro | 2.5 μg/mL |
physical absorption biotransformation | 98% | [ |
|
| 2 × 106 | AFM1 |
in vivo | 50 µg /mL |
physical absorption metabolism mitigation | 45.17% | [ |
AFB1—aflatoxin B1; AFB2, AFG1, AFG2, AFM1—aflatoxin B2, G1, G2, M1; ZEN—zearalenone; B[a]P—benzopyrene.
Yeast strains, their biodetoxification mechanisms, and rates for different food contaminants.
| Probiotic Yeasts Strain/mix | Cell Count CFU/mL | Contaminant | Food/Environment | Contaminant Level | Biodetox. Mechanism | Detox. Rate | Ref. |
|---|---|---|---|---|---|---|---|
| 108 | acrylamide |
fried potato | 1600 μg/kg in the control |
stop formation | 83% | [ | |
| 1.5 × 106 | PAT |
fermentation broth | 500 μg/L |
physical adsorption | 53.97% (6 h fermentation) | [ | |
| 106 | OTA |
wine | 2 µg/kg |
absorption | 29% white win | [ | |
| 4 × 106 | AFB1 |
in vivo—broiler chickens | 1 mg/kg |
↑ excretion | 41–68% | [ | |
| Kyokai 6 | OD4 | As |
in vivo—NCM460 colon epithelium cell HT29-MTX mucosecretory adenocarcinoma cells cooked rice | 30 mg/kg |
binding | 1–6% | [ |
| 1; 5; 7 × 109 | AFB1, AFB2, AFG1, AFG2 |
in vitro in vivo—rats | 50 µg /mL |
Binding absorption | 95.59% | [ | |
|
| 107 | AFM1 |
in vitro | 10 ng/mL |
adsorption desorption | 19, 25, 36% | [ |
PAT—patulin; OTA—ocratoxin; AFB1, AFB2, AFG1, AFG2, AFM1—aflatoxin B1, B2, G1, G2, M1; As—arsenic; ↑—increase.
Other probiotic strains or promising probiotic candidates, their biodetoxification mechanisms, and rates for different food contamination.
| Other Probiotic/Probiotic Candidates Strain /Mix | Cell Count CFU/mL | Contaminant | Food/Environment | Contaminant Level | Biodetox. Mechanism | Detox. Rate | Ref. |
|---|---|---|---|---|---|---|---|
| 50, 70, 100 μL |
|
in vivo in vitro | nm |
growth inhibition | 21 mm B. cereus | [ | |
| 107–108 |
|
rice | 10 / 40 µg/mL |
growth inhibition | 48.49 ± 0.15%/75.26 ± 0.15% | [ | |
| Unknown | ZEN |
in vitro | 2.75 μg/mL |
degradation | 98% | [ | |
| 0.5 OD600 | Pb |
in vitro (MRS) | 50 mg/L |
removing | 80.58 ± 1.65% | [ | |
| 2 × 103 |
|
in vitro (Vero cells) | 2 × 103 |
↓ EHEC growth in co-culture ↓ stx2a expression | 49.6% and 67.8% at 4 and 24 h of cultivation | [ | |
| 109 | Cd |
in vivo mice | 1.6 ± 0.24 μg/mL |
degradation | 80% ↑ survival rate | [ | |
| Unknown | AFB1 |
in vitro | 1 μg/mL |
degradation | 88.34 ± 15.62 | [ | |
|
| 106 | AFM1 |
in vitro | 50 μg/mL |
binding | 58.5% | [ |
| 9.2 | Acrylamide |
rye bread | - |
↓ formation | 38.33% | [ | |
| 107 | AFM1 |
in vitro | 10 ng/mL |
adsorption desorption | 34, 26% | [ | |
| 1010-15 | AFB1 |
in vitro | 5 µg /mL |
binding | 75.06 ± 1.60% | [ | |
| 108 |
|
in vitro (agar) | 106 spores/mL |
growth inhibition—antifungal activity | 20–50% | [ |
B—Bacillus; P.—Pediococcu; E.—Escherichia; ↓—decrease; AFB1, AFM1—aflatoxin B1, M1; ZEN—zearalenone; cadmium—Cd; mercury—Hg; lead—Pb; A.—Aspergillus.
Most used probiotic strains and their impact on different cancers.
| Probiotic Strain | Study Type | Cancer Type/Cell Lines/Carcinogen | Way of Action/Findings | Conditions | Ref. |
|---|---|---|---|---|---|
| In vitro | HT-29 human CRC cells | ↓ proliferation, | 25, 50, and 100 mg/L S-layer protein | [ | |
|
| In vitro | - | Preventive effect | 5 mg Se/L as selenite | [ |
| In vivo | HeLa cervix cancer cells | Sustain apoptosis by ↑ the expression of apoptotic genes | 1.0 × 107 to 1.0 × 108 CFU/mL | [ | |
|
| In vivo | 4T1 breast cancer cells | Improve the capecitabine’s toxicity on 4T1 cells | 1 × 109 CFU/mL | [ |
| In vivo | Colitis-associated cancer C57BL/6 mice | modulate inflammatory responses, inhibit tumor growth, ↓clinical signs of intestinal inflammation | 3 times/week | [ | |
| In vitro | CaCo2 adenoma cells | ↓ proliferation | [ | ||
| In vivo | 76 patients with any solid tumor under therapy | ↓ chemotherapy, radiotherapy, and immunotherapy side effects—diarrhea | 5 drops/day (109 CFU) | [ | |
| In vitro | HT-29 CRC human cells | Induce apoptosis | 0, 100, 200, 400 and 600 μg/mL exopolysaccharides | [ | |
| In vitro | Cancer cells: MCF-7 breast | Antiproliferative and apoptotic effects on MCF-7 | [ | ||
| In vivo | Melanoma cell line B16-F10 injected in | ↓ melanoma occurrence | 109 CFU/mL/day, 7 days prior to and after melanoma injection | [ | |
| In vivo | Gastric cancer-induced in male NMRI inbred albino mice | ↓ tumor volume, size | 1 × 108 CFU/100 µL saline/day | [ | |
| In vitro | SW742 human colon cancer cell line | Necrosis of the tumor cells | Probiotic growth in aerobic conditions, 1 × 105 CFU application on cell | [ | |
| In vivo | Human colorectal cancer | Preventive action | 1/day-5days BB536-y and BB536-y and FOS | [ | |
| In vivo | CRC | Therapeutic action by microbiota modulation, | 2/day | [ | |
| In vitro | CRC SW480 cell line | antiproliferative effect | 1 × 106 cell/mL heat-killed cells | [ | |
| In vivo | SMMC-7721 cancer cell injected into BALB/c nude mice | ↓ tumor growth | 5 × 106 CFUs/100 μL | [ | |
|
| In vivo | Wistar rats Induced CRC | Anticancerigenic action | 1 mL bacterial suspension (108 CFU/mL) 1/day, 6 weeks. by gavage | [ |
↓—decrease/downregulating; ↑—increase/upregulating, CRC—colorectal cancer, IL-6—cytokine related with bad prognosis in advanced cancers, SeCys—selenocysteine, SeMet-L—selenomethionine, CFU—colony formin units, SCFA—short-chain fatty acid, Bcl-2—B-cell lymphoma 2 with role in apoptosis regulation, Bax gene-modulates apoptosis.
Figure 3Anti-carcinogenic mechanisms of probiotics.